For example, telisotuzumab vedotin, a c-MET-directed ADC, has been evaluated in combination with erlotinib, an EGFR tyrosine kinase inhibitor (TKI), in c-MET-positive and EGFR-mutant NSCLC [203, 204]. This evidence concerns the gene MET and non-small cell lung carcinoma.